Navigation Links
Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Date:3/13/2008

from Merck Serono following the completion of two phase 2 clinical trials for adecatumumab. Total operating expenses were $13.1 million for the three months ended December 31, 2007, compared to $10.9 million for the same period in 2006. For the three months ended December 31, 2007, Micromet reported a net loss of $3.8 million, or $0.09 per basic and diluted share, compared to net income of $3.4 million, or $0.11 per basic and diluted share, for the same period in 2006. The positive net income in 2006 was due primarily to the milestone payment received from Merck Serono.

Year Ended December 31, 2007

Revenues for the year ended December 31, 2007 were $18.4 million, compared to $27.6 million for 2006. For the year ended December 31, 2007, Micromet reported operating expenses of $43.6 million, compared to $61.2 million for the same period in 2006. In connection with the merger with CancerVax, Micromet recorded a non-recurring, non-cash charge of $20.9 million in the second quarter of 2006 due to the immediate write-off of CancerVax's in- process research and development programs. For the year ended December 31, 2007, net loss was $20.1 million, or $0.55 per basic and diluted share, compared to $34.0 million, or $1.29 per basic and diluted share, for 2006.

Micromet's cash and cash equivalents were $27.1 million as of December 31, 2007. Net cash used in operating activities was $14.3 million for the year ended December 31, 2007 and $15.4 million in 2006. Based on the status of our development programs, management believes that the cash balance at December 31, 2007 is sufficient to fund operations into the second quarter of 2009.

2008 Outlook:

-- Micromet will present an update on its proprietary BiTE antibody

technology platform and new BiTE antibody programs at the conference of

the American Association of Cancer Research (AACR) in April 2008.

-- A phase 1/2 clinical trial evaluating MT103 in patients wi
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
2. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
3. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
4. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
5. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
6. Helix BioPharma reports Q2 2008 highlights, financial results
7. Oncothyreon reports full year and fourth quarter 2007 financial results
8. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
9. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
10. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
11. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Austin, TX (PRWEB) May 21, 2013 ... and outdoor security solutions, today announced that Genzyme, a ... more units of Door Detective® CL for a multi-use ... already installed in four other Genzyme buildings, this latest ... had with the tailgate detection device improving ...
(Date:5/21/2013)... , May 21, 2013  MacroGenics, Inc. today ... of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody ... the HER2 oncoprotein," will be presented at the ... Clinical Oncology during the Developmental Therapeutics - Immunotherapy ... 4:15 – 4:30 PM.  The presentation will describe ...
(Date:5/21/2013)... NANONEX CORPORATION, a pioneer and ... announced the successful delivery and installation of a ... to a major Japanese manufacturing company. ... advanced nanoimprint lithography tool that has the ability ... sizes and types. Based on Nanonex inventions and ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 PathoGenetix, Inc., ... bacterial strain typing, announced today that it has successfully ... E. coli strains obtained from the Centers for Disease ... Scanning™ (GSS™) technology. The findings are detailed in a ... the American Society for Microbiology in Denver on Monday. ...
Breaking Biology Technology:Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 3MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3Nanonex Announces the Shipment and Installation of an Innovative Nanoimprint Lithography System for Fully Automated Manufacturing 2New Genotyping System Identifies Pathogenic E. coli Outbreak Strains 2New Genotyping System Identifies Pathogenic E. coli Outbreak Strains 3
... 2011 China PharmaHub Corp. (OTC Bulletin Board: ... today announced that it has signed a exclusive worldwide ... rights to develop, commercialize and market a universal donor ... UCSD Associate Professor of Medicine and Pediatrics Dr. Ewa ...
... FREMONT, Calif. and SAN CARLOS, Calif., March 21, ... WGBS ), a leading developer of ... a leader in innovative genomic samples preparation, today ... integrated workflows for gene expression profiling and target ...
... N.J., March 21, 2011 Intrasphere Technologies ( ... solutions firm that provides services to Life Sciences ... SafetyXpress for Argus is Intrasphere,s proprietary implementation accelerator ... Safety suite. Intrasphere is a Specialized Oracle Argus ...
Cached Biology Technology:China PharmaHub In-Licenses Universal Donor Red Blood Cells Technology Exclusively From University of California, San Diego 2WaferGen and NuGEN Announce Agreement to Co-Develop Integrated Workflows Using SmartChip System and SPIA® for Single Cell Analysis, FFPE and Next Generation Sequencing 2WaferGen and NuGEN Announce Agreement to Co-Develop Integrated Workflows Using SmartChip System and SPIA® for Single Cell Analysis, FFPE and Next Generation Sequencing 3WaferGen and NuGEN Announce Agreement to Co-Develop Integrated Workflows Using SmartChip System and SPIA® for Single Cell Analysis, FFPE and Next Generation Sequencing 4Intrasphere Technologies Launches SafetyXpress(TM) for Oracle(R) Argus Safety 2
(Date:5/21/2013)... scientists have charted the path of insulin action in ... a comprehensive blueprint for understanding what goes wrong in ... Humphrey and Professor David James from Sydney,s Garvan Institute ... online edition of the prestigious journal Cell Metabolism ... plays a very important role in the body because ...
(Date:5/20/2013)... effect of physical education (PE) on child weight, but ... the amount of time that elementary schoolchildren spent in ... study represents some of the first evidence of a ... forthcoming in the Journal of Health Economics . ... be viewed at: http://www.sciencedirect.com/science/article/pii/S0167629613000556 , The research ...
(Date:5/20/2013)... Bristol and published online today in the Journal ... brain and inner ear developed in dinosaurs. , ... with Tom Hbner from the Niederschsische Landesmuseum in Hannover, ... dinosaurs. , The two palaeontologists studied different fossils of ... young (juvenile) individual of approximately three years of ...
Breaking Biology News(10 mins):Insight into the dazzling impact of insulin in cells 2Insight into the dazzling impact of insulin in cells 3Gym class reduces probability of obesity, study finds for first time 2Fossil brain teaser 2
... German . , What is the role of phosphorus ... for the nutrition and balance of a forest ecosystem? How can ... in mobile internet access? How do the modern arts experience, perceive ... the interpretation of artistic creations in general? These are just some ...
... shrink diagnostics to fit in a person,s pocket, one question ... liquid. University of Washington researchers have built and patented a ... conduct medical or environmental tests., "This allows us to move ... of layout that we want," said Karl Bhringer, a UW ...
... life scientists from Europe and around the world were ... Forty-eight of the researchers are from Europe and neighbouring ... and the United States join as Associate Members. In ... in the international scientific community. EMBO elects new ...
Cached Biology News:DFG establishes 10 new priority programs 2DFG establishes 10 new priority programs 3Portable diagnostics designed to be shaken, not stirred 2
... using Mo Bio luciferase assay. Mo Bio Laboratories ... will allow you to certify your products ATP-Free ... you to deliver them to your customers in ... limit is 3.5 x 10-12 /l, which will ...
... 'A New Concept in Microarrays: Biomedical ... chip technologies GmbH (Jena, Germany) have collaborated ... new CLONDIAG ArrayTube System. The DNAscope ... technology. The new DNAscope AT automatically reads ...
... LC Sciences provides a comprehensive ... protein kinase substrate (PKS) peptide microarrays ... proteomic scale kinase profiling, quantitative measurement ... discovery research. This comprehensive service includes ...
... The JNK (c-Jun NH2-terminal kinase) ... three identified MAP kinase pathways in ... response to environmental stress, is associated ... itself, and is implicated in the ...
Biology Products: